drugset
Drugs / Paclitaxel protein-bound particles
last change May 2023 re-read 3 minutes ago

Paclitaxel protein-bound particles

also known as Abraxane

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT00262067 Background Dec 2005 → Jul 2008 breast cancer Genentech, Inc. Unknown No outcome recorded

Press releases naming this drug 17 releases

DateIssuerRelease
2023-05-02 American Regent, Inc. American Regent® Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) americanregent.com ↗
2022-04-12 Apotex Inc. Apotex Corp. Launches Generic of Abraxane® in the United States apotex.com ↗
2020-06-17 Genentech, Inc. Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer gene.com ↗
2019-12-03 Genentech, Inc. FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2019-08-29 Hoffmann-La Roche European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2019-05-30 BeOne Medicines BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer beonemedicines.com ↗
2019-03-11 Hoffmann-La Roche Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane roche.com ↗
2019-03-11 Hoffmann-La Roche FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2019-03-08 Genentech, Inc. FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer gene.com ↗
2019-01-16 Genentech, Inc. FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2018-11-12 Genentech, Inc. FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer gene.com ↗
2018-10-22 Genentech, Inc. Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone gene.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Paclitaxel protein-bound particles “Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV” NCT00262067 ↗
Known as Abraxane “Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV” NCT00262067 ↗
Route Intravenous “Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV” NCT00262067 ↗